BPC-157 FDA Status 2026: Is It Approved?
Short answer: no. As of July 2026, BPC-157 is not FDA approved for any human use, and no compliant pharmacy is compounding it. But the status is more specific than a plain yes or no, and it is about to be reconsidered. On July 23, 2026 the FDA Pharmacy Compounding Advisory Committee reviews BPC-157 for the 503A Bulks List. This page lays out exactly where the peptide stands, how it got here, and what the July decision could and could not change.
Is BPC-157 FDA Approved?
No. There is no FDA-approved BPC-157 product. No company has submitted a new drug application for it, no BPC-157 preparation has cleared FDA review for safety and effectiveness, and the agency has publicly stated the peptide is not approved for human use. Every product on the market labeled BPC-157 is either sold as a research chemical or prepared outside the FDA-approved drug system.
That matters because "FDA approved" is a specific legal status, not a quality endorsement people assume. An approved drug has gone through clinical trials and a manufacturing review. BPC-157 has done neither. For the broader picture of which peptides sit where, see our overview of peptides that could become legal to compound again in 2026.
Approved vs Legal: Two Different Questions
People conflate "is it legal" with "is it approved." They are separate. FDA approval means a finished drug passed review. Legality of sale is about how a substance is marketed and whether it is controlled. BPC-157 is not a controlled substance, so possessing it is not a criminal matter, but it is also not an approved drug, which is why it is sold under a research-use label rather than as medicine.
A third status sits in between: whether pharmacies may legally compound it. That is the exact question the July 2026 advisory meeting addresses, and it is separate from full approval. Our FDA Category 2 explainer walks through the compounding framework in detail.
The 2023 Category 2 Decision (Why Compounding Stopped)
In 2023 the FDA sorted peptides nominated for 503A compounding into interim categories. BPC-157 landed in Category 2, the group the agency flagged for significant safety risks. A Category 2 placement is a signal that a substance should not be compounded while the review continues, and compliant 503A pharmacies stopped supplying it.
This is the moment the accessible, pharmacy-made version of BPC-157 disappeared. What remained was the research-chemical market, which has no FDA oversight of purity, dose accuracy, or sterility. For how this fits the wider crackdown, read our FDA peptide ban guide.
The July 23, 2026 PCAC Review
The FDA Pharmacy Compounding Advisory Committee meets July 23-24, 2026 at the agency's White Oak campus in Silver Spring, Maryland, to reconsider seven peptides for the 503A Bulks List. BPC-157 is on the first day. Per the FDA's published agenda, the specific use under review is ulcerative colitis, not the sports-injury or gut-healing uses BPC-157 is marketed for online.
The committee hears the evidence, takes public comment, and votes on a recommendation. That recommendation is non-binding: the FDA usually follows its advisory panels but is not required to. So July 23 is a signal, not a verdict.
BPC-157 shares the July 23 session with KPV (wound healing and inflammatory conditions), TB-500 (wound healing), and MOTS-c (obesity and osteoporosis). The full agenda and the July 24 peptides are covered in our PCAC hearing preview.
What the FDA Staff Position Signals
Ahead of the meeting the FDA released briefing documents for each peptide. As reported by outlets covering the hearing, agency review staff recommend against adding the seven peptides, including BPC-157, to the compounding list, citing insufficient human evidence on safety and effectiveness. Briefing documents reflect staff analysis, not the committee's vote.
There is a political layer worth noting without overstating it: peptides have public backing from the current HHS leadership, and several committee members have industry ties. That tension, career reviewers cautious, appointed advisers more open, is why the outcome is genuinely uncertain rather than a foregone conclusion.
What Actually Changes After July 23
If the committee recommends inclusion and the FDA agrees, 503A pharmacies would have a legal path to compound BPC-157 again for the reviewed use. That is a meaningful shift for access, but it is still not full drug approval, and it would apply to a specific indication rather than the everything-cures marketing common online.
If the committee recommends against, or the FDA declines to add it, BPC-157 stays where it is: unapproved, not compoundable through compliant pharmacies, and available only as a research chemical. Either way, a finished, FDA-approved BPC-157 drug is not on the table in 2026.
The Research-Chemical Reality
Because no approved or compounded version is available, most BPC-157 sold today ships as a lyophilized powder labeled "research use only." No agency verifies what is in the vial. Independent testing of the gray-market peptide supply has repeatedly found underdosed, contaminated, or misidentified product. The label is a legal shield for the seller, not a quality guarantee for the buyer.
If you are researching the compound, our factual guides on BPC-157 dosage, side effects, and the actual evidence behind its benefits stick to what the research does and does not show.
How BPC-157 Compares to Other Peptides
BPC-157 is not alone in this limbo. TB-500, KPV, and MOTS-c share the same July 23 review and the same Category 2 history. It is often stacked with TB-500 for recovery; how those two differ is covered in our BPC-157 vs TB-500 comparison. What separates BPC-157 from GLP-1 drugs is stark: semaglutide and tirzepatide are approved medicines with large trials, while BPC-157 has neither.
For the regulatory contrast on the GLP-1 side, see how the FDA is handling compounded semaglutide and tirzepatide differently from research peptides.
What This Means If You Use or Are Considering BPC-157
Practically: there is no FDA-approved way to buy BPC-157 as medicine in July 2026, and compliant pharmacies are not compounding it. Anything available is unregulated. If the July review goes favorably, that could change for a narrow indication over the following months, on the FDA's timeline, not immediately.
Anyone considering it should treat the current supply as unverified and discuss it with a clinician who knows their history. This page tracks regulatory status, not medical advice.
Frequently Asked Questions About BPC-157
No. As of July 2026, BPC-157 is not approved by the FDA for any human use. There is no approved drug application for it, and no BPC-157 product has passed FDA review for safety, effectiveness, or manufacturing quality. Any product sold as BPC-157 is either a research chemical or a compounded or unapproved preparation, not an FDA-approved medicine.
In 2023 the FDA placed BPC-157 in Category 2 of its interim review of bulk substances used in 503A compounding. Category 2 means the agency identified significant safety risks. Compounding pharmacies that follow FDA guidance stopped using it because a Category 2 placement signals the substance should not be compounded while the review is pending.
The FDA Pharmacy Compounding Advisory Committee (PCAC) meets July 23-24, 2026 to reconsider seven peptides for the 503A Bulks List. BPC-157 is on the July 23 agenda, evaluated for ulcerative colitis. The committee makes a non-binding recommendation; the FDA decides afterward whether to add BPC-157 to the list of substances pharmacies may compound.
No. The PCAC review is about whether compounding pharmacies may use BPC-157 as a bulk substance, not about full FDA drug approval. Even a favorable recommendation would only open a path to legal compounding, not approve BPC-157 as a finished drug. Full approval would require a sponsor to run clinical trials and file a new drug application, which no company has done.
BPC-157 is widely sold labeled "for research use only, not for human consumption." Selling it that way exists in a gray area rather than a clearly legal market. It is not a controlled substance, but it is also not an approved or (currently) compoundable drug, so a research-use label is how vendors work around that. The World Anti-Doping Agency bans it in sport.
The FDA has stated BPC-157 is not approved for human use and, in its 2023 Category 2 placement, cited significant safety concerns and limited human data. Ahead of the July 2026 meeting, FDA review staff published briefing documents that, as reported, recommend against adding the peptide to the compounding list on the grounds that the evidence for safety and effectiveness is insufficient.
A licensed clinician can recommend it, but they cannot obtain an FDA-approved BPC-157 product because none exists, and compliant compounding pharmacies are not making it while it sits in Category 2. Some clinics source it as a research chemical, which carries no FDA oversight of purity or dosing. That is the practical gap the July 2026 review is meant to address.
Semaglutide and tirzepatide are FDA-approved drugs with brand versions (Ozempic, Wegovy, Mounjaro, Zepbound) backed by large trials. BPC-157 has no approved version and no large human trials. The two are on opposite ends of the regulatory spectrum: one is an approved medicine sometimes compounded, the other is an unapproved peptide the FDA is still deciding whether to allow in compounding at all.